180 related articles for article (PubMed ID: 22695301)
21. [Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy].
Brunner J; Seybold U; Gunsenheimer-Bartmeyer B; Hamouda O; Bogner JR;
Dtsch Med Wochenschr; 2010 Jun; 135(23):1166-70. PubMed ID: 20514595
[TBL] [Abstract][Full Text] [Related]
22. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
[TBL] [Abstract][Full Text] [Related]
23. Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting.
d'Arminio Monforte A; Gianotti N; Cozzi-Lepri A; Pinnetti C; Andreoni M; di Perri G; Galli M; Poli A; Costantini A; Orofino G; Maggiolo F; Mazzarello G; Celesia BM; Luciani F; Lazzarin A; Sighinolfi L; Rizzardini G; Bonfanti P; Perno CF; Antinori A;
Antivir Ther; 2014; 19(3):319-24. PubMed ID: 24036891
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.
Young J; Scherrer AU; Günthard HF; Opravil M; Yerly S; Böni J; Rickenbach M; Fux CA; Cavassini M; Bernasconi E; Vernazza P; Hirschel B; Battegay M; Bucher HC;
HIV Med; 2011 May; 12(5):299-307. PubMed ID: 20955357
[TBL] [Abstract][Full Text] [Related]
25. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
[TBL] [Abstract][Full Text] [Related]
26. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Staszewski S; Babacan E; Stephan C; Haberl A; Carlebach A; Gute P; Klauke S; Hermschulte Y; Stuermer M; Dauer B;
J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
[TBL] [Abstract][Full Text] [Related]
27. Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results.
Voigt E; Wasmuth JC; Vogel M; Mauss S; Schmutz G; Kaiser R; Rockstroh JK
Infection; 2004 Apr; 32(2):82-8. PubMed ID: 15057572
[TBL] [Abstract][Full Text] [Related]
28. [Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
Brunet-François C; Taieb A; Masquelier B; Le Moing V; Lewden C; Dellamonica P; Cuzin L; Allavena C; Spire B; Chêne G; Raffi F;
Med Mal Infect; 2007 Mar; 37(3):172-7. PubMed ID: 17239554
[TBL] [Abstract][Full Text] [Related]
29. Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
Péré H; Charpentier C; Mbelesso P; Dandy M; Matta M; Moussa S; De Dieu Longo J; Grésenguet G; Abraham B; Bélec L
AIDS Res Hum Retroviruses; 2012 Apr; 28(4):315-23. PubMed ID: 21942692
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
31. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS
HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
[TBL] [Abstract][Full Text] [Related]
32. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
Bierman WF; van Agtmael MA; Nijhuis M; Danner SA; Boucher CA
AIDS; 2009 Jan; 23(3):279-91. PubMed ID: 19114854
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
34. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
[TBL] [Abstract][Full Text] [Related]
35. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
[TBL] [Abstract][Full Text] [Related]
36. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
Burgos J; Crespo M; Falcó V; Curran A; Navarro J; Imaz A; Domingo P; Podzamczer D; Mateo MG; Villar S; Van den Eynde E; Ribera E; Pahissa A
J Antimicrob Chemother; 2012 Oct; 67(10):2479-86. PubMed ID: 22729925
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
[TBL] [Abstract][Full Text] [Related]
38. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
Jarrin I; Hernández-Novoa B; Alejos B; Santos I; Lopez-Aldeguer J; Riera M; Gutiérrez F; Rubio R; Antela A; Blanco JR; Moreno S;
HIV Med; 2014 Oct; 15(9):547-56. PubMed ID: 24655804
[TBL] [Abstract][Full Text] [Related]
39. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
Masquelier B; Pereira E; Peytavin G; Descamps D; Reynes J; Verdon R; Fleury H; Garraffo R; Chêne G; Raffi F; Brun-Vézinet F;
J Clin Virol; 2005 May; 33(1):75-8. PubMed ID: 15797369
[TBL] [Abstract][Full Text] [Related]
40. Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen.
Burgos J; Crespo M; Falcó V; Curran A; Imaz A; Domingo P; Podzamczer D; Mateo MG; Van den Eynde E; Villar S; Ribera E
J Antimicrob Chemother; 2012 Jun; 67(6):1453-8. PubMed ID: 22378681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]